Revolution in the treatment of Gaucher disease?
Research led by the Protein Engineering and Nanomedicine Group, highlighted in the print and digital edition of the newspaper La Vanguardia.
The NanoERT nanomedicine platform, co-developed by the Protein Engineering and Nanomedicine Group of the IBB, the Vall d'Hebron Research Institute (VHIR) and the Príncipe Felipe Research Center (CIPF), aims to improve enzyme replacement therapies for #Gaucher disease and other rare diseases.
This research was highlighted yesterday in the La Vanguardia newspaper and you can access it here (in Catalan).